ASCO: Study Confirms Pemetrexed-Platinum Activity in Malignant Mesothelioma
Source: Medpage Today
Once again, a study has demonstrated that the combination of pemetrexed with either cisplatin or carboplatin has demonstrated activity in previously untreated malignant pleural mesothelioma. The pemetrexed-cisplatin group led to an overall response rate of 26.3% in 745 mesothelioma patients, and the combination of pemetrexed and carboplatin was associated with an overall response rate of 21.6%. The differences in the response rates are not considered statistically-significant. One-year survival was 63 to 64% and the median time to progression was about seven months with both regimens.
These results come from an analysis of 1,704 chemotherapy-naïve malignant pleural mesothelioma patients, including 1,497 patients with response data. They were among more than 3,000 mesothelioma patients worldwide who received pemetrexed alone or in combination with a platinum agent.
The results were reported at a medical conference and as a published abstract and should be considered preliminary until they appear in a peer-reviewed journal.